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Abstract: BACKGROUND Sepsis is a pathological host response to infection leading to vascular barrier
breakdown due to elevated levels of angiopoietin-2 (Angpt-2) and vascular endothelial growth factor-A
(VEGF-A). Here, we tested a novel heterodimeric bispecific monoclonal IgG1-cross antibody of Angpt-
2 and VEGF - termed ”A2V.” METHODS Cecal ligation and puncture was used to induce murine
polymicrobial sepsis. Organs and blood were harvested for fluorescence immunohistochemistry and RT-
PCR, and survival was recorded. In vitro endothelial cells were stimulated with plasma from septic
shock patients costimulated with A2V or IgG antibody followed by immunocytochemistry and real-time
transendothelial electrical resistance. RESULTS Septic mice treated with A2V had a reduced induction of
the endothelial adhesion molecule ICAM-1, leading to a trend towards less transmigration of inflammatory
cells (A2V: 42.2 ± 1.0 vs. IgG 48.5 ± 1.7 Gr-1+ cells/HPF, p = 0.08) and reduced tissue levels of
inflammatory cytokines (e.g., IL-6 mRNA: A2V 9.4 ± 3.2 vs. IgG 83.9 ± 36.7-fold over control, p =
0.03). Endothelial permeability was improved in vivo and in vitro in stimulated endothelial cells with
septic plasma. Survival was improved by 38% (p = 0.02). CONCLUSION Dual inhibition of Angpt-2
and VEGF-A improves murine sepsis morbidity and mortality, making it a potential therapeutic against
vascular barrier breakdown.
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Abstract
Background: Sepsis is a pathological host response to infec-
tion leading to vascular barrier breakdown due to elevated 
levels of angiopoietin-2 (Angpt-2) and vascular endothelial 
growth factor-A (VEGF-A). Here, we tested a novel heterodi-
meric bispecific monoclonal IgG1-cross antibody of Angpt-2 
and VEGF – termed “A2V.” Methods: Cecal ligation and punc-
ture was used to induce murine polymicrobial sepsis. Organs 
and blood were harvested for fluorescence immunohisto-
chemistry and RT-PCR, and survival was recorded. In vitro 
endothelial cells were stimulated with plasma from septic 
shock patients costimulated with A2V or IgG antibody fol-
lowed by immunocytochemistry and real-time transendo-
thelial electrical resistance. Results: Septic mice treated with 
A2V had a reduced induction of the endothelial adhesion 
molecule ICAM-1, leading to a trend towards less transmi-
gration of inflammatory cells (A2V: 42.2 ± 1.0 vs. IgG 48.5 ± 
1.7 Gr-1+ cells/HPF, p = 0.08) and reduced tissue levels of in-
flammatory cytokines (e.g., IL-6 mRNA: A2V 9.4 ± 3.2 vs. IgG 
83.9 ± 36.7-fold over control, p = 0.03). Endothelial permea-
bility was improved in vivo and in vitro in stimulated endo-
thelial cells with septic plasma. Survival was improved by 
38% (p = 0.02). Conclusion: Dual inhibition of Angpt-2 and 
VEGF-A improves murine sepsis morbidity and mortality, 
making it a potential therapeutic against vascular barrier 
breakdown. © 2019 S. Karger AG, Basel
Introduction
Sepsis is characterized as a life-threatening organ dys-
function caused by an overwhelming host response to an 
infection [1]. Sepsis is one of the most frequent causes of 
emergency admission and counts responsible for approx-
imately 11% of all admissions to intensive care units in 
high-income countries [2]. Its incidence is rising [1, 3] 
and globally more than 5 million septic people die every 
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single year [4]. The mortality rate has recently been found 
to be up to 59% in septic shock patients in Germany [3]. 
General therapeutic management is mostly based on the 
administration of anti-infectives and source control. Be-
sides these direct treatments against the infection, only 
supportive strategies (fluid resuscitation, vasopressors, 
low tidal volume ventilation [5], etc.) have been estab-
lished. So far, there is no specific agent to causally treat 
the pathological host response in sepsis. Despite intensive 
research, novel innovative therapies that worked in mice 
have largely failed to proof efficacy in clinical trials [6]. It 
has been assumed that the negative clinical trial results 
are due to poor animal models of sepsis [6] and the het-
erogeneity of the immune response in men – a fact that is 
further aggravated by the absence of monitoring tools of 
a single patients’ immune status. What might help one 
patient at an early disease state might actually harm an-
other. The need for a promising new therapeutic target 
that might be tailorable to individual needs of a given pa-
tient is more important than ever [7, 8].
The physiological vascular response to a local infection 
includes the controlled recruitment and transmigration 
of neutrophils both by activating the endothelium and 
then increasing its permeability. As part of the patholog-
ical (systemic) host response in sepsis, this highly regu-
lated molecular mechanism regulating the physiological 
processes of local inflammatory responses occurs in a 
rather uncontrolled fashion, leading to global vascular 
leakage and massive infiltration of inflammatory cells. 
Together, this aggravates multi organ failure and contrib-
utes to death. This vascular response to infection is less 
heterogenous and appears to be continuously aggravating 
over time as the disease progresses. Therefore, the dys-
functional endothelium might represent a promising tar-
get for the development of novel therapeutic strategies 
against sepsis morbidity and mortality [9].
The vascular endothelial growth factor (VEGF)/VEGF 
receptor as well as the angiopoietin (Angpt)/Tie2 system 
are both ligand-tyrosine kinase receptor systems that are 
almost exclusively expressed in the vasculature and can 
modify endothelial inflammation, vascular hemostasis, 
vasomotor tone, and importantly the vascular barrier. In 
sepsis, it has been shown that circulating levels of VEGF-
A [10, 11] and Angpt-2 [12, 13] are elevated (leading to 
activation of the VEGF receptor and deactivation of Tie2, 
respectively). These events contribute to endothelial bar-
rier breakdown and tissue inflammation, leading to vas-
cular leakage with hypovolemia, tissue edema, altered mi-
crocirculatory flow, and ultimately to multiple organ dys-
function.
Kienast et al. [14] used the complementary effects of 
VEGF-A and Angpt-2 on the vasculature to modulate 
neoangiogenesis in cancer. To target both ligands simul-
taneously, the authors developed a heterodimeric bispe-
cific IgG1 antibody via the CrossMAb technology [15] 
termed Angpt2-VEGF CrossMAb (or short A2V). A2V 
combines bevacizumab on one arm and LC06 on the oth-
er arm. Over the last decade, we and others have shown 
that targeting Tie2 by modulating circulating ligands 
(e.g., genetic depletion, siRNA, synthetic activation, 
ABTAA) can improve survival in animal models of the 
disease by up to 50%. Interestingly, the effect of Angpt-2 
inhibition by antibodies was only very mild or even ab-
sent [16]. Positive effects on survival and endothelial per-
meability in sepsis have also been reported for VEGF-A 
inhibition using bevacizumab [17].
Based on these facts and the theoretical benefits of an 
antibody strategy, we designed a preclinical proof-of-
principle study to investigate the putative beneficial effect 
of dual inhibition of Angpt-2 and VEGF-A with a novel 
heterodimeric bispecific antibody (A2V).
Material and Methods
Antibodies and Reagents
All chemicals and reagents were purchased from Sigma-Al-
drich (St. Louis, MO, USA) unless otherwise specified.
CrossMAb Antibody
The dual Angpt-2-VEGF-A (A2V) antibody (Roche No. 
R06872840-000-006) is based on a combination of LC06 (anti-mu-
rine/human Angpt-2) and B20-4.1 (anti-murine/human VEGF-
A). Mouse isotype antibody of unknown specificity was used as 
control (Roche No. 0437-0004). Antibodies were dissolved in so-
dium chloride 0.9% and injected in mice intraperitoneally or were 
applied to human umbilical vein endothelial cell (HUVEC) cul-
ture. A2V CrossMAb and IgG control were kindly provided by 
pRED, F. Hoffmann LaRoche (Basel, Switzerland). A2V is gener-
ated as described elsewhere [18].
Animal Studies
All experiments were approved by the local committee for care 
and use of laboratory Animals (LAVES Lower Saxony, reference 
No. AZ/12-0681) and were performed according to international 
guidelines on animal experimentation. Male C57BL/6 mice (8–10 
weeks old, weighing 20–25 g) were purchased from Charles River 
Laboratories (Sulzfeld, Germany) and Central Animal Facility of 
Hanover Medical School and maintained under standard condi-
tions. One hour prior to polymicrobial sepsis induction by cecal 
ligation puncture (CLP), mice were treated with single intraperi-
toneal injection (30 mg/kg body weight) of IgG-control or A2V 
antibodies, respectively. Anesthesia was induced by 3.5% isoflu-
rane and maintained with 1.5% isoflurane (Baxter, Unter-
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nol, then a median laparotomy was performed to expose the ce-
cum. The cecum was then ligated and punctured once with a 20-G 
needle. For sham mice, this step was skipped. After closing the 
abdomen by two-layered suturing, all mice were resuscitated sub-
cutaneously with 200 µL of 0.9% saline. To avoid hypothermia, 
mice were kept warm by an infrared lamp in the perioperative set-
ting. Sixteen hours post CLP, mice were sacrificed to harvest or-
gans or to perform functional analysis of permeability. Organs 
were either shock-frozen in liquid nitrogen for further molecular 
analysis or were collected in PBS for later paraffin embedding for 
histology.
Measurements of Serum Parameters
Serum analysis of lactate dehydrogenase, blood urea nitrogen, 
glutamate-pyruvate transaminase, and glutamic oxaloacetic trans-
aminase were measured by an automated method using OLYM-
PUS AU 400 (Beckman Coulter, Krefeld, Germany).
RNA Purification and Quantitative PCR
The RNeasy Mini Kit (Qiagen, Hilden, Germany) and the 
RNeasy-Micro-Kit (Qiagen Technologies, Hilden, Germany) were 
used to extract total RNA from organ tissue or cultured cells, re-
spectively, per manufacturers’ instructions. Via the Transcriptor 
First Strand cDNA Synthesis Kit (Roche Diagnostics, Rotkreuz, 
Switzerland) added by FastStart Taq DNA Polymerase, dNTPack 
(Roche Diagnostics, Rotkreuz, Switzerland) 1 µg of total RNA was 
then reverse transcribed to cDNA followed by SYBR Green real-
time quantitative PCR using LightCycler 480 II (Roche, Basel, 
Switzerland). For primers purchased from Qiagen, we used SYBR 
Premix Ex Taq II Takara (CLONTECH TAKARA) as DNA poly-
merase. For all other primers, we used TaqMan® Universal Master 
Mix (Thermo Fisher Scientific, Waltham, MA, USA). The follow-
ing specific primers were used for quantification: murine β-actin 
(Fw: CCT GAG CGC AAG TAC TCT GTG T; Rev: CTG CTT 
GCT GAT CCA CAT CTG), murine Angpt-2 (Fw: GCT GAA 
GGA CTG GGA AGG C; Rev: GGA CTC TTC ACC AGC GAG 
GTA), murine intercellular adhesion molecule-1 (ICAM-1; detect-
ed transcript QT00155078; Qiagen, Hilden, Germany), murine tu-
mor necrosis factor (TNF)-α (detected transcript QT00104006; 
Qiagen, Hilden, Germany), murine interleukin (IL)-6 (detected 
transcript: NM_031168; Qiagen, Hilden, Germany), murine vas-
cular cell adhesion molecule-1 (VCAM-1; Fw: ACA TCC CTC 
CAC AAG GCT TCA AGA; Rev: TGG CAT TTC CTG AGA GAA 
GCT GGA), human β-actin (Fw: CTG GAA CGG TGA AGG TGA 
CA; Rev: AGT CCT CGG CCA CAT TGT G).
For each sample, triplicate RT-qPCR analyses were performed, 
and the mean of the obtained threshold cycle values (CT) was tak-
en. Gene expression was standardized to the expression of the 
housekeeping gene (murine or human β-actin), yielding the ΔCT 
value.
Primary HUVEC Culture
Informed consent was obtained from all HUVEC donors and 
approved from the ethical committee of Hannover Medical School 
(No. 1303-2012). Cell isolation was conducted in accordance with 
institutional and governmental guidelines. Cells were isolated 
from human umbilical veins with the help of heat-inactivated fetal 
bovine serum (Thermo Fisher Scientific, Waltham, MA, USA), 
phosphate-buffered saline (Thermo Fisher Scientific, Waltham, 
MA, USA), trypsin/ethylenediaminetetraacetic acid solution (Bio-
chrom, Berlin, Germany), and collagenase (Biochrom, Berlin, Ger-
many). Cells were used at passage P3–P5. Culturing was performed 
in endothelial cell growth medium containing 2% fetal bovine se-
rum according to the manufacturer’s instructions (Lonza, Basel, 
Switzerland). Unless otherwise stated, HUVECs were stimulated 
with 50 ng/mL recombinant human TNF-α (R&D Systems, Min-
neapolis, MN, USA) to induce a sepsis-like phenotype.
Fluorescent Immunohistochemistry in HUVECs
Coverslips were coated with collagen (Sigma-Aldrich, St. 
Louis, MO, USA), upon which HUVECs were grown to conflu-
ency. Cells were then preincubated with starvation medium 
(EBM2 + 0.5% FCS + gentamicin) for 3.5 h. Afterwards, either 4 
µg/mL IgG control or A2V was added for 1 h followed by stimu-
lation with 5% septic plasma for 30 min. At the end of the ex-
periment, cells were fixed with 4% paraformaldehyde, blocked 
with 10% donkey serum (Jackson Immuno Research Inc., West 
Grove, PA, USA) and permeabilized with 0.1% Triton X-100 in 
PBS (Sigma-Aldrich, St. Louis, MO, USA). Coverslips were then 
incubated with primary antibody against VE-cadherin (CD144; 
BD Pharmingen, Heidelberg, Germany) for 1 h at room tem-
perature. As a secondary antibody, anti-Actin Alexa Fluor 546 
Phalloidin (Thermo Fisher Scientific, Waltham, MA, USA) was 
used. 4′,6-diamidino-2-phenylindole (DAPI; SIGMA-Aldrich, 
St. Louis, MO, USA) for 10 s stained the nucleus. Finally, the 
coverslips were affixed with aqua-poly/mount (Polysciences 
Inc., Eppelheim, Germany). The images were taken with a Leica 
DMI 6000B microscope and were all obtained with the same 
gain, exposure, and offset conditions.
Fluorescent Immunohistochemistry
Paraffin-embedded sections (1.5 µm) from lung and kidneys 
were labelled with primary antibody against Gr-1 (AbD serotec, 
Puchheim, Germany). As secondary antibodies, we used goat an-
ti-rat IgG-HRP (Santa Cruz Biotechnology, CA, USA). Cryosec-
tions (6 μm) were blocked with 10% donkey serum (Jackson Im-
muno Research Inc., West Grove, PA, USA) and stained with pri-
mary antibody against ICAM-1 (or M19; Santa Cruz Biotech- 
nology). As secondary antibody, goat anti-rabbit IgG-HRP (Santa 
Cruz Biotechnology, CA, USA) was used. For global histomor-
phologic analysis of lungs, we used periodic acid-Schiff (PAS) 
staining.
Electric Cell-Substrate Impedance Sensing
Transendothelial electrical resistance (TEER) was measured 
using an electric cell-substrate impedance sensing (ECIS) system 
(Applied BioPhysics Inc., New York, NY, USA). Values were 
pooled at discrete time points and plotted versus time. Each condi-
tions’ end resistance was divided by its starting resistance to give 
the normalized TEER. Confluence was determined by the mono-
layer achieving manufacturer-recommended electric criteria.
Septic Shock Patients
To generate an in vitro assay to investigate the phenotype of the 
septic endothelium, we stimulated HUVECs by supplementing the 
media with 5% plasma from two different patients suffering from 
early-onset (< 12 h) and very severe (norepinephrine dose > 0.4 μg/
kg/min) septic shock. The plasma was originally obtained in the 
context of another study (No. 2786-2015) [19]. Patients agreed 
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Statistical Analysis
For all analysis and graph creation, we used Graph Pad Prism 
5 (La Jolla, CA, USA). Results are expressed as mean ± SD unless 
otherwise noted. Differences between groups were calculated with 
one-way ANOVA and non-parametric Mann-Whitney U test and 
considered significant with two-tailed p value < 0.05. Survival data 
were analyzed through a log-rank test and visualized by Kaplan-
Meier curves. Serum measurements were analyzed with unpaired 
t test with Welch’s correction.
Results
A2V Modulates Endothelial Adhesion Molecule 
Expression
Given the importance of endothelial activation in the 
process of recruiting leukocytes to local sites of tissue in-
flammation, we first analyzed the expression of adhesion 
molecules in murine experimental sepsis. Fluorescent 
immunohistochemistry in renal tissue revealed a marked 
increase in peritubular and glomerular ICAM-1 expres-
















































































ICAM DAPI AF ICAM DAPI AF
Fig. 1. A2V modulates endothelial adhesion molecule expression. 
Fluorescent immunohistochemistry for intercellular adhesion 
molecule (ICAM)-1 (red) was performed 16 h after cecal ligation 
puncture (CLP) or sham surgery in A2V (30 mg/kg) or IgG control 
antibody (IgG)-treated mice (nuclear staining with 4′,6-diamidi-
no-2-phenylindole, blue; autofluorescence is shown in green). 
Representative results for each group (n = 6–8) are shown in peri-
tubular (a) or glomerular regions (b), respectively. c Semi-quanti-
fication of whole kidney cross-sections was assessed by a single 
blinded operator ranging from 1 = mild, 2 = moderate to 3 = severe. 
d Real-time quantitative polymerase chain reaction in kidney was 
used to quantify ICAM-1 messenger RNA (mRNA) as in the 
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markedly reduced in the A2V-treated animals compared 
to IgG control (IgG)-treated ones (Fig. 1a, b, lower panels, 
and Fig. 1c). Additionally, RT-PCR revealed a trend to-
wards reduced ICAM-1 (Fig. 1d) and VCAM-1 mRNA 
expression in whole kidney lysates.
A2V Reduces Tissue Infiltration of Inflammatory Cells 
and Cytokine Production
Next, we investigated if this reduction in adhesion 
molecule expression led to reduced transmigration of in-
flammatory neutrophils and less tissue cytokine produc-
tion. Given that the highest number of transmigrated 
neutrophils can regularly be seen in lungs, we primarily 
investigated the pulmonary capillaries for Gr-1+ cell infil-
tration by fluorescent immunohistochemistry. Upon ex-
perimental sepsis induction, Gr-1+ cells were increasing-
ly recognized in the alveolar capillary space (Fig. 2a, high-
lighted by white arrowheads). This influx of Gr-1+ cells 
was noticeably reduced in A2V-treated animals (Fig. 2a, 
lower right image). Semi-quantification of Gr-1+ neutro-
phil expression revealed a trend towards reduction upon 
A2V treatment (Fig. 2b). The same observation was true 
for local production of a key cytokine of sepsis, i.e., IL-6 
investigated by RT-PCR on mRNA level in kidneys and 
lungs (Fig. 2c, d). Similar trends were seen for TNF-α.
A2V Affects Permeability in vivo and in vitro
To asses vascular permeability in vivo, we used classi-
cal histology with PAS staining to assess a phenomenon 
termed “peribronchial cuffing,” which visualizes the pres-
ence of lung edema on the morphological level. Figure 3a 
shows representative slides obtained from septic and 
sham mice treated with A2V or IgG. The occurrence of 
cuffing is highlighted with red arrows around the arterio-
lae (as vasa vasorum of the adjacent bronchus – that also 
both share one adventitia). Semi-quantification revealed 
not only a significant increase of cuffing upon sepsis in-
duction (sham: 0.6 ± 0.4 vs. CLP: 2.5 ± 0.5, p < 0.0001) but 
also a reduction in the A2V group compared to IgG (A2V: 
1.4 ± 0.3 vs. IgG: 2.5 ± 0.5, p = 0.002) (Fig. 3b).
To directly test a potential anti-permeability effect of 
A2V, we used in vitro models with stimulated HUVECs 
and assessed morphological changes by fluorescent im-
munocytochemistry of a major adherens junction pro-
tein (i.e., VE-cadherin – in green) as well as the cytoskel-
etal architecture by F-actin (in red). To induce the phe-
notype of a septic endothelium with vascular leakiness, 
we challenged the HUVECs with plasma from 2 exem-
plary septic shock patients. Both upper panels of Figure 
4a show the typical cellular correlate of barrier dysfunc-
tion (i.e., disruption of VE-cadherin and the formation 
of actin stress fibers together leading to gaps between 
adjacent cells). These morphological changes are pro-
tected when cells were co-incubated with A2V (lower 2 
panels). Here, VE-cadherin is continuously expressed at 
cell-cell contacts and F-actin is configurated in a cortical 
manner, thereby generating a force that presses each cell 
towards another. To quantify these qualitative observa-
tions, we used real-time measurements of the endothe-
lial integrity by TEER measurements using the ECIS de-
vice. Adding septic plasma to endothelial cells induced 
an acute drop in resistance (i.e., permeability) that could 
be prevented when the cells were co-incubated with 
A2V (Fig. 4b).
Effect of A2V on Organ Function and Survival
Sixteen hours after sepsis induction, we observed a 
slight increase in blood urea nitrogen as an indicator of a 
beginning acute kidney injury. Liver enzymes and lactate 
dehydrogenase as global markers for tissue injury were 
analogously elevated. All these surrogates of organ dys-
function showed trends towards improvement in the 
A2V-treated group (Table 1). Lastly, we analyzed if the 
earlier described effects on functionally relevant changes 
in experimental sepsis might indeed improve clinically 
relevant outcomes. The Kaplan-Meier graph in Figure 5 
shows the survival of A2V-pretreated mice (–1 h) com-
pared to the IgG control antibody (IgG) in a polymicro-
bial CLP sepsis model. Two different A2V doses (10 mg/
kg [Fig. 5a] and 30 mg/kg body weight [Fig. 5b]) were as-
sessed. The higher dose showed a survival benefit of 
36.4% (p = 0.02) in a CLP model adjusted to a 90% mor-
tality.
Discussion
Here, we tested for the first time a dual pharmacologi-
cal blockade of Angpt-2 and VEGF-A in a polymicrobial 
murine model of experimental sepsis using a novel het-
erodimeric bispecific monoclonal antibody. Although we 
and others have proposed that Angpt-2 directly contrib-
utes to sepsis morbidity and mortality [12, 13], treatment 
strategies with monoclonal antibodies (as a delivery plat-
form) against Angpt-2 have been mostly disappointing. 
Therapeutic VEGF blockade by antibodies has also shown 
mixed results [17, 20–22]. Here we found that dual block-
ade of both Angpt-2 and VEGF-A led to reduced endo-
thelial inflammation and vascular permeability, leading 



























































































































































































Fig. 2. A2V reduces tissue infiltration of inflammatory cells and 
cytokine production. a Fluorescent immunohistochemistry of 
granulocyte differentiation antigen (Gr)-1 (red) was performed 
16 h after cecal ligation puncture (CLP) or sham surgery in A2V 
(30 mg/kg) or IgG control antibody (IgG)-treated mice (nuclear 
staining with 4′,6-diamidino-2-phenylindole, blue; autofluores-
cence is shown in green). Arrowheads indicate Gr-1-positive cells. 
Representative results for each group are shown (n = 6–8). b Semi-
quantification of whole lung cross-sections by evaluating Gr-1+ 
cells per high power field (HPF) (HPF = 40× magnification) 
(** p < 0.01). c Real-time quantitative polymerase chain reaction 
from kidneys and lungs (d) for interleukin-6 (IL-6) messenger 


















































































































Fig. 3. A2V affects permeability in vivo. a Periodic acid-Schiff 
staining of paraffin-embedded lung tissue 16 h after cecal ligation 
puncture (CLP) in A2V (30 mg/kg) or IgG control antibody (IgG)-
treated mice showing less peribronchial cuffing (red arrows) in 
CLP mice after A2V treatment compared to control. Representa-
tive images of n = 4–5/group are shown. All images show bronchus 
and their corresponding arteriola (as vasa vasorum of the bron-
chus surrounded by one common adventitia). b Semi-quantifica-
tion of peribronchial cuffing was performed by surveying whole 
lung sections. Scoring considered the degree of edema and was 
done by a single blinded operator (0 = no cuffing, 1 = mild cuffing, 






















Table 1. Serum surrogates of organ dysfunction
Sham CLP
IgG A2V IgG A2V
LDH, U/L 282.0±39.0 290.5±48.6 768.5±124.0 490.9±76.6
p = 0.08*
BUN, mmol/L 8.9±0.8 9.5±0.7 17.2±4.6 9.9±1.3
p = 0.16*
GPT, U/L 65.2±23.4 52±8.922 158.8±22.8 127.3±17.1
p = 0.29*
GOT, U/L 137.7±38.8 126.6±36.6 336.6±35.4 127.3±17.1
p = 0.21*
CLP, cecal ligation puncture; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; GPT, glutamate-
pyruvate transaminase; GOT, glutamic oxaloacetic transaminase.
*
 Unpaired t test with Welch’s correction between the following groups: CLP A2V vs. CLP veh.
For clarity reasons not assigned in table: CLP A2V vs. sham veh.: LDH, p = 0.03; BUN, p = 0.53; GPT, p = 0.06; 
GOT, p = 0.01. CLP A2V vs. sham A2V: LDH, p = 0.05; BUN, p = 0.82; GPT, p = 0.003; GOT, p = 0.009. CLP veh. 
vs. sham veh.: LDH, p = 0.004; BUN, p = 0.10; GPT, p = 0.02; GOT, p = 0.003. CLP veh. vs. sham A2V: LDH, p = 
0.004; BUN, p = 0.13; GPT, p = 0.001; GOT, p = 0.002. Sham A2V vs. sham veh.: LDH, p = 0.9; BUN, p = 0.54; 









































































Hauschildt et al.J Vasc Res8
DOI: 10.1159/000503787
What was the rationale to explore yet another angio-
poietin/Tie2 modulating strategy given that other ap-
proaches have been more or less successfully investigated 
in recent years (Table 2)? Monoclonal antibodies are 
nowadays on everyone’s lips and represent a drug type 
used on a daily basis for numerous diseases – in some 
cases with clinical experience over decades (e.g., CD-20 
antibodies against B-cell lymphoma) [23]. More and 
more novel specific antibodies have been developed and 
in 2017 alone, a total of 17 novel monoclonal antibodies 
have been approved by the FDA (around 30 in 2018). 
Therefore, we believe that this class of drug might have 
the most realistic potential with regard to drug develop-
ment from bench to bedside in a translational research 
context. Yet, exactly this type of drug did not convince 
with regard to hard end points in preclinical models of 
sepsis compared to other compounds. For example, 
Ziegler et al. [16] did investigate a monoclonal Angpt-2 
antibody (LC-10, Roche) in murine sepsis. In general, 
they focused on septic cardiomyopathy and elegantly 
found improvements in many surrogate end points, but 
overall survival was only very mildly influenced (10–20%) 
[16]. In our own hands, blockade of Angpt-2 with a 
monoclonal antibody did not improve survival in murine 
sepsis at all. Although, clinically less feasible than a mono-
clonal antibody approach, most published strategies 
showed survival benefits around 40–50% (summarized in 
Table 2) in these preclinical studies. For VEGF blockade, 
the data were similarly mixed [17, 20–22]. Based on the 
appealing drug formulation of an antibody and the ad-
vanced stage of development of the A2V (four different 
bispecific antibodies based on the CrossMAb technology 
are currently in active phase 1/2 clinical trials [18] for 
colorectal cancer studies and the first is yet to enter phase 
3 trial for diabetic macula edema), we aimed at investigat-
ing specifically this novel heterodimeric bispecific mono-
clonal IgG1-cross antibody of Angpt-2 and VEGF.
Indeed, combining both Angpt-2 and VEGF-A block-
ing strategies in one bispecific antibody, we observed a 
survival benefit of almost 40%. Again, this effect is in line 
with other knockout experiments and Angpt/Tie2 or 
VEGF modulating therapies (Table 2). Although similar-
ly effective, all these potential therapies are at earlier stag-
es of development from bench to bedside, making the 
A2V antibody approach clinically more attractive. The 
underlying reason why the combination of Angpt-2 and 
VEGF-A antibodies might be more effective than indi-
vidual ones alone remains unanswered by this project. In 
the oncology field, it has been proposed that tumor mi-
crovasculature can develop resistance against single anti-
angiogenic agents and that the combination of 2 of them 
might overcome this problem. If this theory is transfer-
able to an acute setting such as sepsis is unclear.
Given that A2V does not interfere with the infection 
(here a ruptured colon) per se, yet improves survival by 





































Fig. 4. A2V affects permeability in vitro. a Fluorescence immuno-
cytochemistry staining for vascular endothelial cadherin (VEC, 
green) and F-actin (red) was performed on confluent human um-
bilical vein endothelial cells (HUVECs). First, HUVECs were in-
cubated with A2V (30 mg/kg) or control IgG antibody (IgG) and 
then challenged for 30 min with media supplemented with 5% 
plasma from two individual septic shock patients. b Normalized 
transendothelial electrical resistance was longitudinally measured 
in real time in HUVECs with an electric cell-substrate impedance 
sensing device. HUVECs were first co-incubated with A2V or IgG 
control antibody followed by stimulation with 5% plasma from 



































































































































Table 2. Potential treatment options that interact in the Angpt-2/VEGF axis











COMP-Ang1 LPS/mouse Reduced vascular leak and inflammation Hwang et al. [25] 2009 Preclinical
Angiopoietin-1
variant
COMP-Ang1 LPS/mouse Decreases acute kidney injury, reduces
renal vascular leak and inflammation
Kim et al. [26] 2009 Preclinical
Agonistic 7-mer
peptide
Vasculotide LPS /mouse Pretreatment improved survival by 41.4% David et al. [27] 2011 Preclinical
Agonistic 7-mer
peptide
Vasculotide CLP/mouse Survival benefit: pretreatment HR 0.39
(0.19–0.81), rescue treatment HR 0.22
(0.06–0.83)
Kümpers et al. [28] 2011 Preclinical
Recombinant
agonist
rh-Ang1 CLP/mouse Improvement of MODS and survival time
(around 10% vs. 0% after 36 h)
David et al. [29] 2011 Preclinical
More stable Ang-1
variant
MAT.Ang1 LPS/mouse Improved vascular leak, microvascular
flow, and inflammation





Reduction of permeability in lung injury Gutbier et al. [31] 2017 Preclinical
Angpt-2 Genetic depletion siRNA LPS, CLP/mouse Improvement of kidney function and
survival by 50%
Stiehl et al. [32] 2016 Preclinical
Inhibitor LC06/LC10 LPS, CLP/mouse Improves survival by 10–20%, reduced
permeability and pericyte loss
Ziegler et al. [16] 2013 Preclinical
Simvastatin Inhibition of Angpt-2
biosynthesis
CLP/mouse Improved survival by 37.5% Ghosh et al. [33] 2015 Preclinical
Flunarizin Inhibition of Angpt-2
biosynthesis and release
LPS/mouse Improved pulmonary endothelial
inflammation and survival by 25%
Retzlaff et al. [34] 2017 Preclinical
Ang-2/Tie2 clustering
→ activates Tie2
ABTAA LPS, CLP, S. aureus
peritonitis
Improvement of MODS and survival by
50% as pretreatment
Han et al. [35] 2016 Preclinical
Tie2 small molecule
inhibitor of VE-PTP –
activates Tie2





CLP/mouse Reduced production of IL-6 and IL-10 Nolan et al. [22] 2004 FDA approval
of aflibercept
Various Ad-sFlt-1, antibodies
against Flk-1 and Flt-1
CLP/mouse Reduction in VEGF levels, improved
leakage, cardiac function, and survival
Yano et al. [20] 2006 Preclinical
VEGF Trap sFLT-1 (soluble vascular
endothelial growth factor
receptor-1)
LPS, CLP/mouse Attenuated inflammatory responses and
improved survival (up to 60 % in pre-
treatment)
Tsao et al. [37] 2007 Preclinical
VEGF-A antibody Bevacizumab LPS, CLP/mouse Improves survival by almost 40% in CLP,
decreasing inflammatory responses and
endothelial permeability
Jeong et al. [38] 2013 FDA approved
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40%, might sound surprising. We believe that the vascu-
lature that builds a physical border for any inflammatory 
cell between the blood circulation and sites of (local) in-
fection plays a central role in the pathological (systemic) 
host response. By blocking excessive endothelial adhe-
sion molecule expression and permeability literally any-
where in the body, A2V might be able to reduce organ 
failure due to edema and uncontrolled inflammation, 
thereby improving survival. On the other hand, this 
means that a complete blockade of these pathways might 
– at least theoretically – lead to an ultra-strong endothe-
lial barrier unable to guide any inflammatory cell from 
the circulation to a local infection, a situation that defi-
nitely would not be desirable. Therefore, correct dosing 
and timing is crucial and should be the focus of extensive 
additional benchwork besides our proof of principle 
study presented here.
We find the in vitro experiments assessing permeabil-
ity upon challenge with real septic shock plasma particu-
larly interesting. This plasma must contain countless cy-
tokines and injurious molecules that by themselves might 
induce endothelial inflammation and permeability. Yet, 
we observed that dual inhibition of Angpt-2 and VEGF-A 
alone is sufficient to block the development of vascular 
leakage. This might indicate that these two pathways in-
deed play a critical role in septic barrier breakdown.
The study has limitations. First of all, as this was a 
proof of principle study, we focused on a pretreatment 
rather than a rescue strategy. The potential negative 
consequences of blocking vascular inflammation and 
permeability were just eluded and require further ex-
periments to identify ideal dosing and timing strategies. 
The synergistic role of Angpt-2 and VEGF-A inhibition 
was mechanistically not analyzed in our project but de-
serves further clarification. Methodologically, it is im-
portant to mention that the analysis of vascular leakage 
in vivo by bronchiolar cuffing was only semi-quantita-
tive.
In conclusion, this study is the first that investigates a 
novel heterodimeric bispecific monoclonal IgG1-cross 
antibody of Angpt-2 and VEGF-A in experimental mu-
rine sepsis. It shows improved endothelial inflammation 
and permeability, ultimately leading to a survival benefit 
of almost 40%.
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Fig. 5. A2V improves survival in experimental sepsis. Kaplan-Meier survival analysis after CLP-induced sepsis 
in mice treated with 10 mg/kg body weight A2V (n = 10) or IgG control antibody (IgG) (n = 11) (a) and 30 mg/
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